Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy
TORONTO, ON / ACCESSWIRE / January 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The sub-study will evaluate the drug as a potential rescue therapy for critically severe COVID-19 cases.
Dr. Par Nijhawan, Chief Executive Officer of Edesa, said that physicians involved in the company s ARDS study identified a number of COVID-19 patients who they believed could benefit from the experimental treatment, but were too ill to be considered for the main study. This sub-study will allow us to potentially expand the use of EB05 to critically ill patients suffering
A Chinese cohort study published earlier this month in
The Lancet medical journal found that over 75% of patients that were previously hospitalised with Covid-19 had at least one lingering symptom six months later.
These symptoms range from muscle weakness and fatigue, anxiety and depression, to more severe respiratory issues. These long-term effects of the virus are what some scientists are calling long Covid.
However, while this study is one of the first large studies on long Covid, much remains uncertain about the virus’ lasting impact on the body.
“We’re not 100% sure how many people are going to suffer from ongoing symptoms.
January 25, 2021 Share
The WHO started by saying that there is no evidence that the virus can spread through food – provided it is cooked at more than 60 degree Celsius. What they have neglected to say is that the chicken is handled by you long before it is cooked
By the time you read this lakh of chickens will have died of Avian Flu. Some will have died naturally. Others will have been beaten to death or strangled.
How many do you think will be buried or burnt? Very few. Most of them will land on your plate, sold at reduced prices by the poultries.
Share this article
Share this article
PALM BEACH, Fla., Jan. 25, 2021 /PRNewswire/ Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been revolutionizing the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer. An article in Nature.com recently said that: The paramount achievement in cancer treatment in the last decade has undoubtedly been the introduction of T cell targeted immunomodulators blocking the immune checkpoints CTLA-4 and PD1 or PDL1… Anti-PD1/PDL1 antibodies have become some of the most widely prescribed anticancer therapies. T-cell-targeted immunomodulators are now used as single agents or in combination with che
Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.